Watch Ticker

89bio, Inc. Common Stock

Go to 89bio, Inc. Common Stock Website

$9.66

0.32 (3.43%)

Live

Previous Close

$9.34

Day Range

$9.14 - $9.79

Previous Day Range

$9.115 - $9.545

Market Cap

$1.3 billion USD

Day Vol.

1.1 million

Previous Day Vol.

981452

Currency

USD

Primary Exchange

Nasdaq

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.

Related tickers: AZN, NBIX, SPRB, CRNX, BBIO, IONS, ARWR, ETNB.

Read Full Article

N/A - 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

89bio, a clinical-stage biopharmaceutical company, announced the grant of non-qualified stock options to four new employees as an inducement to join the company.

Related tickers: ETNB.

Read Full Article

Trending Tickers

Please sign in to view